Immunotherapy for Cancer Treatment
Medically reviewed by Omar Castaneda Puglianini, MD, Blood and Marrow Transplant and Cellular Immunotherapy Program
Immunotherapy is a type of cancer treatment that helps the immune system better recognize and fight cancer cells. Different forms of immunotherapy, such as checkpoint inhibitors, CAR-T cell therapy, TIL therapy, and cancer vaccines, work in different ways to strengthen the body’s defenses against cancer. New forms of immunotherapy are being researched every day and will continue to impact the way we approach cancer treatment moving forward.
Schedule an appointment to discuss your eligibility for treatment. Call us at 1-888-663-3488 or request a consultation online.
Immunotherapy has proven more successful in treating certain types of cancer than others. New forms of immunotherapy are being researched every day and will continue to impact the way we approach cancer treatment moving forward.
How does immunotherapy work?
Immunotherapy can help your immune system better recognize cancer cells and fight them. There are several types of immunotherapies. Some treatments help strengthen your immune system overall, while others help your immune system recognize and attack cancer cells more specifically.
This is important because your immune system normally protects your body by identifying and attacking things that do not belong, such as germs, but cancer can be more difficult for the immune system to recognize because cancer cells develop from your own healthy cells. As these cells gradually change into cancer cells, the immune system may not recognize them as harmful.
Types of immunotherapy
There are several types of immunotherapy used to treat cancer. Each works in a different way to help your immune system recognize, target, or destroy cancer cells. Your care team will determine whether immunotherapy is appropriate for you based on your type of cancer and other factors.
- Adoptive cell transfer – This treatment uses your own immune cells, called T cells, to fight cancer. T cells are collected from your body and prepared or modified in a laboratory to help them better recognize and attack cancer cells. The cells are then given back to you. Examples include CAR T-cell therapy, TIL therapy and TCR therapy.
- Cancer vaccines – Unlike vaccines that help prevent infections, cancer treatment vaccines are designed to help your immune system recognize and fight cancer cells.
- Cytokines – Cytokines are proteins that occur naturally in your body and help control how your immune system works. Certain laboratory-made cytokines can be used to stimulate the immune system and help it fight cancer.
- T-cell engagers (TCE) – These treatments are specially designed antibodies that help bring immune cells called T cells into close contact with cancer cells, making it easier for the T cells to attack them. Bispecific and Trispecific T-cell engagers (BiTEs & TriTEs) are types of T-cell engagers.
- Immune checkpoint inhibitors – Cancer cells can sometimes use natural "brakes" in the immune system to avoid being attacked. Checkpoint inhibitors help release these brakes, allowing your immune system to better recognize and attack cancer cells.
- Monoclonal antibodies – These are specially designed antibodies made to recognize specific targets on cancer cells and may work in different ways to help your immune system find and fight cancer.
- Oncolytic viruses – These treatments use specially selected or modified viruses that infect and destroy cancer cells. They can also help stimulate an immune response against the cancer.
- Other immunotherapies – Other treatments may help strengthen or stimulate your immune system so it can better recognize and fight cancer.
World Leader in CAR T Therapy
Request an AppointmentMoffitt has been a driving force in getting several cellular immunotherapies FDA-approved and continues to lead in expanding cellular immunotherapy options for patients. Today, several FDA-approved cellular therapies are available for certain types of cancer. Whether one of these treatments is appropriate for you depends on your type of cancer, treatments you have already received and other individual factors. Your care team can help you understand your options. Examples of FDA-approved cellular immunotherapies include:
- Lifileucel (AMTAGVI®) – A type of tumor-infiltrating lymphocyte (TIL) therapy for certain adults with melanoma that cannot be removed with surgery or has spread to other parts of the body and has continued to grow after previous treatments.
- Axicabtagene ciloleucel (YESCARTA®) – A CAR T-cell therapy used to treat certain adults with large B-cell lymphoma or follicular lymphoma when the cancer has not responded to treatment or has returned. Eligibility depends on the type of lymphoma and treatments you have previously received.
- Brexucabtagene autoleucel (TECARTUS®) – A CAR T-cell therapy for adults with mantle cell lymphoma or B-cell precursor acute lymphoblastic leukemia (ALL) that has returned or has not responded to treatment.
- Obecabtagene autoleucel (AUCATZYL®) – A CAR T-cell therapy for adults with B-cell precursor acute lymphoblastic leukemia (ALL) that has returned or has not responded to treatment.
- Idecabtagene vicleucel (ABECMA®) – A CAR T-cell therapy for adults with multiple myeloma that has returned or has not responded to treatment after at least two previous lines of therapy that included certain types of myeloma medicines.
- Ciltacabtagene autoleucel (CARVYKTI®) – A CAR T-cell therapy for adults with multiple myeloma that has returned or has not responded to treatment after at least one previous line of therapy. Specific eligibility depends on the treatments you have previously received and how your cancer responded to them.
- Lisocabtagene maraleucel (BREYANZI®) – A CAR T-cell therapy used to treat several types of blood cancer, including certain large B-cell lymphomas, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), follicular lymphoma, mantle cell lymphoma and marginal zone lymphoma. Eligibility depends on the type of cancer and treatments you have previously received.
Important: Not every cellular immunotherapy is appropriate for every patient. FDA-approved uses and treatment options can change over time. Your care team will consider your diagnosis, previous treatments, overall health and other factors when determining which treatment options may be right for you.
Monoclonal antibody therapy
Monoclonal antibody treatment involves administering monoclonal antibodies to a patient to help destroy their cancer cells. An antibody is a Y-shaped protein that binds to a foreign invader (antigen), signaling to other immune cells that they need to attack it (in some cases, the antibody will destroy the invader on its own). A monoclonal antibody, in turn, is a man-made version of an antibody that’s produced in a laboratory.
During cancer-related monoclonal antibody infusion, monoclonal antibodies bind to both cancer cells and immune system cells, either marking the cancer cells so that the immune system can attack them or bringing the two types of cells close enough together that the immune system can destroy the malignancy.
Cytokine therapy
As was mentioned above, cytokine therapy involves using man-made cytokines to treat cancer. A cytokine is a type of protein that helps control the growth and activity of immune system cells and blood cells. With regard to cancer treatment, specifically, cytokines are able to send signals that help destroy cancer cells and enable normal cells to live longer. Other types of cytokines can be used to either prevent or manage the side effects associated with chemotherapy, thereby also assisting in the fight against cancer.
Florida's First NCI-designated Comprehensive Cancer Center
Recognized for its scientific excellence, Moffitt is the state's longest-established National Cancer Institute-designated Comprehensive Cancer Center.
Oncolytic virus therapy
Viruses are usually something we try to avoid. However, researchers have learned that certain viruses can be used to help treat cancer. These are called oncolytic viruses. They are naturally occurring or genetically modified viruses that can preferentially infect and destroy cancer cells while limiting damage to healthy cells. Oncolytic virus therapy is considered a form of cancer immunotherapy because, in addition to directly killing cancer cells, it can help the immune system recognize and attack the cancer.
How does it work? Viruses reproduce by entering cells and using those cells to make more copies of themselves. Oncolytic viruses take advantage of this process to target cancer. In many cases, the virus is injected directly into a tumor. The virus enters cancer cells, reproduces inside them, and eventually causes the cells to break apart and die. This process is called cell lysis. When the cancer cells break apart, they release substances called tumor antigens. These antigens can act like signals that help the immune system recognize the cancer. Once activated, immune cells may attack remaining cancer cells in the treated tumor and, in some cases, may also recognize cancer cells elsewhere in the body. In this way, oncolytic virus therapy has two potential effects: directly destroying cancer cells and helping the immune system develop a stronger response against the cancer.
Oncolytic viruses are selected or engineered to preferentially target cancer cells, which helps limit their effects on normal cells. However, no cancer treatment is completely free of risk. Side effects vary depending on the virus being used, the type and location of the cancer, how the treatment is given, and the patient’s overall health. Your cancer care team can explain the expected benefits and potential side effects of a particular therapy.
Are oncolytic viruses already being used to treat cancer? Yes, talimogene laherparepvec (T-VEC) became the first FDA-approved oncolytic virus therapy in the United States in 2015. T-VEC is made from a genetically modified herpes simplex virus and is used to treat certain patients with melanoma whose tumors cannot be completely removed with surgery. Many other oncolytic viruses are being studied in clinical trials. Researchers are investigating their use in different cancers and are also studying whether combining oncolytic viruses with other treatments, such as immune checkpoint inhibitors, can improve the immune response against cancer.
Researchers are also exploring new ways to deliver these therapies. Although oncolytic viruses are often injected directly into tumors, researchers are investigating whether some can be given intravenously, allowing the virus to travel through the bloodstream and potentially reach tumors in different parts of the body. Oncolytic virus therapy remains an active area of cancer research and represents an innovative approach that brings together virology, cancer biology, and immunotherapy to help the immune system recognize and fight cancer.
How is immunotherapy administered?
Immunotherapies may be administered either into a vein (intravenously), by an injection, under the skin (subcutaneously) or into a muscle (intramuscularly). Certain types of immunotherapy may be delivered directly to the body cavity where the tumor is located.
What cancers can be treated by immunotherapy?

Immunotherapy is used to treat many different types of cancer. However, it may not be the right treatment for every patient or every type of cancer. Your care team will consider several factors, including the type and stage of your cancer, your overall health, and the specific features of your cancer, to determine whether immunotherapy may be an option for you.
Immunotherapy may be used to treat:
- Bladder cancer
- Brain cancer
- Breast cancer
- Cervical cancer
- Colorectal cancer
- Esophageal cancer
- Head and neck cancers
- Kidney cancer
- Leukemia
- Liver cancer
- Lung cancer
- Lymphoma
- Melanoma
- Multiple myeloma
- Ovarian cancer
- Pancreatic cancer
- Prostate cancer
- Sarcoma
- Skin cancer
- Stomach cancer
Your care team can explain whether immunotherapy is available for your specific type of cancer and discuss its potential benefits and risks with you.
Side effects of immunotherapy

Like other cancer treatments, immunotherapy can cause side effects. The side effects you may experience depend on the type of immunotherapy you receive, and they can be different for each person. Some side effects may occur during treatment, while others can develop after treatment has ended. Some common side effects may include:
- Fatigue
- Fever
- Shortness of breath
- Nausea or vomiting
- Diarrhea
- Headache
- Decreased appetite
- Rash
- Itching
In some cases, immunotherapy can cause the immune system to affect healthy parts of the body, leading to inflammation. These reactions can sometimes be serious, so it is important to let your care team know about any new or worsening symptoms, even if they seem minor or occur after you have finished treatment. Some symptoms that may need prompt medical attention include:
- Liver inflammation (hepatitis): Yellowing of the skin or eyes, severe nausea or vomiting, or dark-colored urine.
- Inflammation of the colon (colitis): Diarrhea, abdominal pain, or bloody or black stools.
- Lung inflammation (pneumonitis): New or worsening cough, shortness of breath, or chest pain.
- Problems affecting the brain or nervous system: New or worsening confusion, severe headache, unusual sleepiness, memory problems, or other changes in thinking or behavior
- Kidney problems: Changes in the amount or color of urine, blood in the urine, decreased appetite, or swelling around the ankles
- Eye problems: Blurry or double vision, eye redness, or eye pain
If you develop any new or worsening symptoms during or after immunotherapy, contact your care team promptly. They can help determine whether your symptoms are related to treatment and whether additional evaluation or treatment is needed.
Immunotherapy clinical trials
Clinical trials are an important part of developing and improving cancer treatments. Researchers are studying new immunotherapies, as well as new ways to use existing immunotherapies, for many different types of cancer. Participating in a clinical trial may give some patients access to new or investigational treatments that are being studied.
Clinical trials may also be an option for patients whose cancer has not responded to standard treatments or for those who are interested in exploring additional treatment options. However, clinical trials are not right for everyone, and investigational treatments may have benefits as well as risks. Your care team can help you understand which clinical trials may be appropriate for you and discuss the potential benefits and risks so you can make an informed decision about participating.
Immunotherapy treatment at Moffitt Cancer Center
At Moffitt Cancer Center, our specialists provide personalized care for patients receiving immunotherapy. Our team works together to carefully monitor each patient’s response to treatment, manage side effects, and adjust the treatment plan when needed. Our physicians and scientists are also actively researching new ways to use the immune system to fight cancer.
Patients may have access to established immunotherapy treatments as well as clinical trials evaluating new approaches, including cellular immunotherapies such as CAR T-cell therapy, tumor-infiltrating lymphocyte (TIL) therapy, and T-cell receptor (TCR) therapy. If you are interested in learning whether immunotherapy may be an option for you, our cancer specialists can review your individual diagnosis and treatment needs and discuss the options that may be appropriate for you.
If you'd like to learn more about immunotherapy, call 1-888-663-3488 or complete a new patient registration form online to request an appointment with an expert at Moffitt. We’re providing each new patient with rapid access to a cancer expert.
References
National Cancer Institute: Immunotherapy to Treat Cancer
National Cancer Institute: Monoclonal Antibodies
National Cancer Institute: FDA Approves Talimogene Laherparepvec to Treat Metastatic Melanoma
National Cancer Institute: Oncolytic Virus Therapy
American Cancer Society: Cytokines and Their Side Effects
Cancer Research Institute: Oncolytic Virus Therapy
Charles River: Oncolytic Viruses
Medical NewsToday: What to know about antibodies